Demystifying Praxis Precision Medicine: Insights From 7 Analyst Reviews
Portfolio Pulse from Benzinga Insights
Praxis Precision Medicine (NASDAQ:PRAX) has been evaluated by 7 analysts over the past three months, with a majority giving bullish ratings. The average 12-month price target has increased to $123.57. Analysts have maintained or raised their ratings, reflecting positive sentiment despite revenue challenges and a high net margin.
June 18, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Praxis Precision Medicine has received predominantly bullish ratings from analysts, with an average 12-month price target of $123.57, reflecting a positive outlook. Despite revenue challenges, analysts maintain or raise their ratings, indicating confidence in the company's future performance.
The majority of analysts have given bullish ratings, and the average price target has increased, indicating positive sentiment. This is likely to have a short-term positive impact on the stock price, despite the company's revenue challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100